These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 4147512)
21. [Clinical experiences with Imagotan]. Iscar G Arch Neurobiol (Madr); 1972; 35(4):367-74. PubMed ID: 4404658 [No Abstract] [Full Text] [Related]
22. [The use of bromperidol in an open study]. Hucker H Int Pharmacopsychiatry; 1978; 13 Suppl 1():53-61. PubMed ID: 35480 [No Abstract] [Full Text] [Related]
23. Clinical experience with pipothiazine palmitate (19552 R.P.) in hospitalized and open ward patients with functional psychoses. Salvesen C; Vaksdal K PDM; 1974; 5-6(9-12;1-8):10-4. PubMed ID: 4156935 [No Abstract] [Full Text] [Related]
24. A study of flupenthixol decanoate and pipotiazine undecylenate in schizophrenics. Astrup C; Grimgård A; Hebnes K; Kruse-Jensen A; Lid M Acta Psychiatr Scand; 1974; 50(5):481-91. PubMed ID: 4156624 [No Abstract] [Full Text] [Related]
25. Potential value of penfluridol and pipothiazine palmitate. Gallant DM Psychopharmacol Bull; 1975 Jan; 11(1):11-2. PubMed ID: 235769 [No Abstract] [Full Text] [Related]
26. Pimavanserin (Nuplazid) for Parkinson's disease psychosis. Med Lett Drugs Ther; 2016 Jun; 58(1496):74-5. PubMed ID: 27249096 [No Abstract] [Full Text] [Related]
27. Safety evaluation of penfluridol, a new long-acting oral antipsychotic agent. Ota KY; Kurland AA; Slotnick VB J Clin Pharmacol; 1974 Apr; 14(4):202-9. PubMed ID: 4595986 [No Abstract] [Full Text] [Related]
28. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials. Citrome L; Meng X; Hochfeld M; Stahl SM Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738 [TBL] [Abstract][Full Text] [Related]
29. [Dynamics and treatment of the tendency to enchronization of schizophrenic psychoses]. López-Ibor Aliño JM Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1973; 1(2):377-88. PubMed ID: 4147379 [No Abstract] [Full Text] [Related]
30. Piperacetazine and chlorpromazine: a comparison. Johnson AC; Kulkarni AS Am J Psychiatry; 1973 May; 130(5):603-5. PubMed ID: 4144711 [No Abstract] [Full Text] [Related]
32. AHR 6134--a new anxiolytic drug with unusual clinical properties. Benber HC; Feldmann H Prog Neuropsychopharmacol; 1978; 2(1):117-22. PubMed ID: 31643 [No Abstract] [Full Text] [Related]
33. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Blin O; Azorin JM; Bouhours P J Clin Psychopharmacol; 1996 Feb; 16(1):38-44. PubMed ID: 8834417 [TBL] [Abstract][Full Text] [Related]
34. Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome--a functional approach. Hillert A; Maier W; Wetzel H; Benkert O Pharmacopsychiatry; 1992 Sep; 25(5):213-7. PubMed ID: 1384075 [TBL] [Abstract][Full Text] [Related]
35. Pilot clinical investigation of risperidone in the treatment of psychotic patients. Gelders YG; Heylen SL; Vanden Bussche G; Reyntjens AJ; Janssen PA Pharmacopsychiatry; 1990 Sep; 23(5):206-11. PubMed ID: 1701262 [TBL] [Abstract][Full Text] [Related]
38. [Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double blind research]. Bures E; Pöldinger W Int Pharmacopsychiatry; 1978; 13 Suppl 1():45-52. PubMed ID: 35479 [No Abstract] [Full Text] [Related]
39. Monotherapy versus polypharmacy for hospitalized psychiatric patients. Case BG; Patrick L; Peselow ED Am J Psychiatry; 2005 Mar; 162(3):632; author reply 632-3. PubMed ID: 15741498 [No Abstract] [Full Text] [Related]
40. Supersensitivity psychosis after tapering aripiprazole: a case report. Chang CC; Hsu WY; Chen SH Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):388-9. PubMed ID: 19166895 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]